Free Newsletter
Novartis, Novo sue Bayer over patent
Novartis and Novo Nordisk are ganging up on Bayer, alleging that the German company's hemophilia treatment Kogenate infringes on one of their joint patents. In a statement, Bayer said it would "vigorously defend itself" against the complaint, and that it doesn't believe it has overstepped the bounds of any patents. The company's stock fell on the news. Meanwhile, other news reports said the suit, filed in federal court in Texas, names Wyeth as well. The New Jersey-based firm has not yet commented.
- see Bayer's release
- read the article at CNN Money
- check out reports of the Wyeth connection at CNN Money
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
SHARE
WITH: